OUR Closer ⭐️ Congrats to Jeff Hoffman on reaching 500 career @MLB strikeouts!

Note the contribution of air pollution particulate matter (PM), a major contributor to developing lung cancer, that was part of this study Link erictopol.substack.com/p/a-n…

If you made it this far, you'll love The Shift. Every day, there's a new AI breakthrough changing how people work and live. We break it down in under 5 minutes a day, so you don't. Plus, get 3,000 AI tools and free AI courses when you join. Subscribe👇 theshiftai.beehiiv.com/subsc…

4 Ballon d'Or in this picture

How much bigger is a trillion than a billion? A million seconds ago: 12 days. ⇨ Your last paycheck A billion seconds ago: 1994. ⇨ Average Birth Year of X User A trillion seconds ago: 32,000 years ago ⇨ Before the last Ice Age.

🚨While @SpaceX goes IPO and the world's glued to @FIFAWorldCup ⚽🚀an interesting paper popped up for your Friday read @NatureMedicine 👉Frontier general LLMs (GPT-5.2, Gemini 3.1 Pro, Claude Opus 4.6) outperformed specialized clinical AI tools (OpenEvidence, UpToDate Expert AI) on medical knowledge, clinician alignment 1,800 blinded physician annotations on real clinical queries🤯 👉This result was unexpected 🤯🤔 👉"Specialized" ≠ "Better" @OncoAlert nature.com/articles/s41591-0…

🟦Nausea-Vomiting Prevention ESMO-MASCC 2023 guideline summary #cancer #oncology #MedX @OncoAlert @CancerCareMASCC

Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO): Results of crossover treatment from a randomized trial of 177Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC). asco.org/abstracts-presentat… The phase II PLUDO trial 🇨🇦compared first-line lutetium-177 PSMA (LuP) versus docetaxel 💊(DOC) in chemotherapy-naïve, PSMA-positive mCRPC. While first-line rPFS was similar, overall survival favored DOC in the intention-to-treat population. Among patients who crossed over at progression and received both therapies, no differences were observed in second-line rPFS, rPFS2, or OS. These findings suggest the OS imbalance was likely driven by unequal crossover rates, highlighting the importance of receiving both treatments. #ProstateCancer @lhscradonc @sebastienhotte @JustinLeeMD @LuciaNappi4 @DiMariaJiang @Yipilimumab @francoisbenard @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer in @ESMO_Open. No benefit of scalp cooling in terms of hair preservation or quality of life.G2 alopecia primary reason for scalp cooling discontinuation. esmoopen.com/article/S2059-7…

Very true and never spoken of x.com/HSRdirector/status/206…

As shown in previous CRC studies, ctDNA positivity captures relapse risk very well. However, ALTAIR does not show that we can meaningfully and durably modify this risk with FTD/TPI. Therefore, in this setting, ctDNA does not appear to function as a predictive tool for treatment selection, but rather as a strong MRD/prognostic enrichment marker. Trying to treat MRD with conventional chemotherapy may not be the most rational approach. The biology of circulating tumor cells or molecular residual disease may differ from that of established tumor deposits in tissue. We need treatment strategies designed specifically around MRD biology, rather than simply moving standard cytotoxic agents earlier into the molecular recurrence setting. nature.com/articles/s41591-0…

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer | OncLive onclive.com/view/vopimetosta…

On the basis of this data, Tango Therapeutics, the company making this drug, has decided to move to a Phase III trial of combination therapy. globenewswire.com/news-relea…

Trying to explain somatostatin receptor PET imaging in as few words as possible for my talk at ENDO2026 next weekend... I have found my previous slides to be too wordy (no surprise to anyone who knows me...😅). How are these for an explanation? My own slide first, then ChatGPT with a prettier slide but I think they complement each other Nuclear Medicine folks: Feel free to make fun of this... I am just a simple chemotherapist... 🤣

I have a new Medscape video in the Skills Lab series where I try to rectify 5 fallacies prevalent in cancer. Here are my 5 axioms dissecting the 5 fallacies- medscape.com/viewarticle/fac… First, more people are dying from cancer X should not imply that the drug approval standards for cancer X should be lowered. Second, a cancer is rare does not automatically imply getting away with lower approval standards. There are nuances including what constitutes “rare”. Third, cancer incidence in population X is increasing should not automatically imply let’s start screening population X even more. Fourth, asking for evidence does not mean someone is against innovation. Fifth, being a clinical expert does not make you an expert for population level decisions.

Is there anything cooler than Vancouver transforming its science center dome into an official World Cup ball? So sick.

Vancouver crushed it with the Science World-to-Giant World Cup Ball conversion. Shoutout to the dude that dropped the final panel for the makeover.

Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial @OncoAlert thelancet.com/journals/langa…

A common sub-analysis in clinical trials is the association of the type of response with survival outcomes, often showing that responders tend to do better. One issue with these analyses is that the causation is often misinterpreted. Patients are implied to have experienced better PFS/OS because of achieving a better response. In truth, the opposite may be true: patients with less aggressive tumors are more likely to stay on treatment for long enough to achieve a deep response. The statistical analysis is also tricky. The Kaplan-Meier PFS/OS curves for responders are usually flat for several months, suggesting “guarantee time bias”: patients who eventually become responders must survive and be progression-free long enough to be classified as responders. In a nutshell, patients may not survive longer because they achieve a deeper response; rather, patients with more favorable timor biology and longer disease control are more likely to remain on treatment long enough to achieve partial or complete response. The same issue applies to analyses of drug toxicities, dose reductions, and irAEs: patients must remain alive and on treatment long enough to experience these events, which can make these groups appear to have better outcomes unless appropriate time-dependent or landmark methods are used. A thorough discussion of this bias is found in this article, published in the inaugural year of @JCO_ASCO (vol 1, 1983). Thanks to @ValenzaCarmine for sharing this article with me. ascopubs.org/doi/10.1200/JCO…

🩸The first randomized controlled trial of a multicancer early detection blood test: Annual Galleri screening reduced stage IV diagnoses by 14% & increased stage I/II detection, though the study didn’t meet its primary endpoint. 🗣️@CharlesSwanton | #ASCO26 ascopost.com/news/june-2026/…